• Healthy Living
Stress may be causing your cravings
Stress may be causing your cravings

Drugs, food and habitual behaviors all have a direct effect on …

You're eating more calories than you think
You eat more calories than you think

"At least two-thirds of all (study) participants underestimated…

McDonald's can't shake criticism about nutrition
McDonald's still rapped over nutrition

McDonald's was taken to task by speakers associated with an …

Cloning stem cells: What does it mean?
Cloning stem cells: What does it mean?

Creating an embryo just from an egg and a skin cell seems like …

5 ways to handle chronic pain
5 ways to handle chronic pain

While pain medications play an important role in the treatment …

Advertisement

Lilly drug chosen for Alzheimer's prevention study

Drug shows promise for milder forms of disease

Updated: Friday, 18 Jan 2013, 4:17 PM EST
Published : Friday, 18 Jan 2013, 4:17 PM EST

(AP) - Researchers have chosen an experimental drug by Eli Lilly & Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.

The drug, called solanezumab, is designed to bind to and help clear the sticky deposits that clog patients' brains.

Earlier studies found it did not help people with moderate to severe Alzheimer's but it showed some promise against milder disease. Researchers think it might work better if given before symptoms start.

"The hope is we can catch people before they decline," which can come 10 years or more after plaques first show up in the brain, said Dr. Reisa Sperling, director of the Alzheimer's center at Brigham and Women's Hospital in Boston.

She will help lead the new study, which will involve 1,000 people ages 70 to 85 whose brain scans show plaque buildup but who do not yet have any symptoms of dementia. They will get monthly infusions of solanezumab or a dummy drug for three years. The main goal will be slowing the rate of cognitive decline. The study will be done at 50 sites in the U.S. and possibly more in Canada, Australia and Europe, Sperling said.

In October, researchers said combined results from two studies of solanezumab suggested it might modestly slow mental decline, especially in patients with mild disease. Taken separately, the studies missed their main goals of significantly slowing the mind-robbing disease or improving activities of daily living.

Those results were not considered good enough to win the drug approval. So in December, Lilly said it would start another large study of it this year to try to confirm the hopeful results seen patients with mild disease. That is separate from the federal study Sperling will head.

About 35 million people worldwide have dementia, and Alzheimer's is the most common type. In the U.S., about 5 million have Alzheimer's. Current medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

Online:

Alzheimer's info: http://www.alzheimers.gov

Alzheimer's Association: http://www.alz.org

  • Comments

Comments WLFI.com is migrating to a more stable commenting system called DISQUS. This system is used by CNN, TIME, FOX News, numerous blogging sites and has over 75 Million registered users. Unfortunately we can't migrate our current user accounts to this new system.

To sign up for a DISQUS account, click the DISQUS button just below and to the right and then click Login.

DISQUS lets you login with several different options, including Facebook, Google, Twitter, Yahoo or OpenID. We expect it to allow more conversation and better moderation. If you have any questions, please feel free to comment below.

 

blog comments powered by Disqus

Advertisement
Advertisement